AFG
RXRX icon

Albion Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Albion Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91K Hold
520
– – ﹤0.01% 551
2026
Q1 		$1.6K Buy
520
+400
+333% +$1.55K ﹤0.01% 590
2025
Q4 		$491 Hold
120
– – ﹤0.01% 608
2025
Q3 		$586 Hold
120
– – ﹤0.01% 605
2025
Q2 		$608 Hold
120
– – ﹤0.01% 539
2025
Q1 		$635 Hold
120
– – ﹤0.01% 555
2024
Q4 		$812 Hold
120
– – ﹤0.01% 622
2024
Q3 		$791 Hold
120
– – ﹤0.01% 464
2024
Q2 		$900 Hold
120
– – ﹤0.01% 464
2024
Q1 		$1.2K Hold
120
– – ﹤0.01% 443
2023
Q4 		$1.18K Hold
120
– – ﹤0.01% 419
2023
Q3 		$918 Hold
120
– – ﹤0.01% 425
2023
Q2 		$897 Sell
120
-4,063
-97% -$28.4K ﹤0.01% 421
2023
Q1 		$27.9K Hold
4,183
– – ﹤0.01% 236
2022
Q4 		$32.3K Buy
4,183
+1
+0% +$10 ﹤0.01% 232
2022
Q3 		$44K Buy
4,182
+4,062
+3,385% +$41.1K ﹤0.01% 219
2022
Q2 		$1K Hold
120
– – ﹤0.01% 503
2022
Q1 		$1K Sell
120
-6,094
-98% -$64.8K ﹤0.01% 569
2021
Q4 		$106K Buy
+6,214
New +$117K 0.01% 243

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Albion Financial Group's RXRX Position: Q2 2026 in Review

Albion Financial Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 520 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #551.

Albion Financial Group first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $106K in Q4 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Albion Financial Group held 520 shares of Recursion Pharmaceuticals worth $1.91K as of Q2 2026.
  • Albion Financial Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Albion Financial Group's portfolio in Q2 2026, its #551 holding.
  • Albion Financial Group first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Albion Financial Group's Recursion Pharmaceuticals position peaked at $106K in Q4 2021.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.